Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $15.2 million.

  • Keros Therapeutics' Accumulated Expenses fell 3155.31% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 3155.31%. This contributed to the annual value of $20.9 million for FY2024, which is 1647.51% up from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Accumulated Expenses is $15.2 million, which was down 3155.31% from $20.0 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Accumulated Expenses peaked at $22.2 million during Q3 2024, and registered a low of $5.5 million during Q1 2021.
  • In the last 5 years, Keros Therapeutics' Accumulated Expenses had a median value of $12.2 million in 2023 and averaged $12.4 million.
  • Per our database at Business Quant, Keros Therapeutics' Accumulated Expenses surged by 8770.55% in 2021 and then tumbled by 3155.31% in 2025.
  • Quarter analysis of 5 years shows Keros Therapeutics' Accumulated Expenses stood at $7.3 million in 2021, then surged by 73.77% to $12.8 million in 2022, then surged by 40.5% to $17.9 million in 2023, then rose by 16.48% to $20.9 million in 2024, then decreased by 27.29% to $15.2 million in 2025.
  • Its last three reported values are $15.2 million in Q3 2025, $20.0 million for Q2 2025, and $17.3 million during Q1 2025.